RBC Capital analyst Conor McNamara maintained a Buy rating on Repligen (RGEN – Research Report) on April 1 and set a price target of $219.00.

Repligen’s strong growth and bioprocessing expansion position it for success. Find out why RGEN stock is a Buy, with a $175 ...

We recently published a list of Top 10 Stocks to Buy According to 12 West Capital Management. In this article, we are going ...

This quarter, Repligen’s $167.5 million of revenue was flat year on year and in line with Wall Street’s estimates. Looking ahead, sell-side analysts expect revenue to grow 9% over the next 12 ...

Shares of Repligen Co. (NASDAQ:RGEN – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ...

Learn more about whether Medpace Holdings, Inc. or Repligen Corporation is a better investment based on AAII's A+ Investor ...

Repligen has acquired 908 Devices' desktop portfolio of four devices for bioprocessing process analytical technology applications for $70 million in cash. Repligen, a Waltham, Mass., life-sciences ...

Learn more about whether Repligen Corporation or Bio-Techne Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

WALTHAM, Mass. and BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc ...

Repligen Corporation (NASDAQ:RGEN), a leading pure-play bioprocess supplier with a market capitalization of $8.17 billion, has been navigating a complex market environment characterized by ...

Repligen purchased 908 Devices’s desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices remains focused on the growth of its newly ...

In this article, we are going to take a look at where Repligen Corporation (NASDAQ:RGEN) stands against other top stocks to buy according to 12 West Capital Management. Joel Ramin founded 12 West ...